Abacus Bioscience Funding & Investors
Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.
abacusbioscience.comTotal Amount Raised: $4,413,591
Abacus Bioscience Funding Rounds
Seed
$4,413,591
Seed Investors
Seagen
Funding info provided by Diffbot.